{"mainPropery":{"diseaseId":2658,"diseaseName":"Tyrosinemia type 1","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/2658/tyrosinemia-type-1","synonyms":["Tyrosinemia type I","Hepatorenal tyrosinemia","Fumarylacetoacetase deficiency","FAH deficiency"],"synonyms-with-source":[{"name":"Tyrosinemia type I"},{"name":"Hepatorenal tyrosinemia"},{"name":"Fumarylacetoacetase deficiency"},{"name":"FAH deficiency"}],"identifiers":[{"identifierType":"OMIM","identifierId":"276700"},{"identifierType":"ORPHANET","identifierId":"882"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":6,"diseaseTypeName":"Digestive Diseases","source":"Orphanet"},{"diseaseTypeId":26,"diseaseTypeName":"Kidney and Urinary Diseases","source":"Orphanet"},{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"},{"diseaseTypeId":37,"diseaseTypeName":"Newborn Screening"},{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":4209,"resourceName":"Tyrosinemia Society, Inc","abbreviation":"","address1":"P.O. Box 11340","address2":"","address3":"","address4":"","address5":"","city":"Huntsville","state":"AL","zip":"35814","country":"United States","phone":"+1-256-684-0601","tty":"","tollFree":"","fax":"","email":"info@tyrosinemia.org","url":"https://www.tyrosinemia.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/276700' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='https://www.ncbi.nlm.nih.gov/pubmed/?term=tyrosinemia+type+1+%5Bti%5D' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Tyrosinemia type 1. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Tyrosinemia+type+1%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Tyrosinemia type 1. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition=tyrosinemia' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Tyrosinemia type 1. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":350,"resourceId":1167,"resourceName":"Baby's First Test","descriptionText":"<a href='https://www.babysfirsttest.org/newborn-screening/conditions/tyrosinemia-type-i' target='_blank'>Baby's First Test</a> is the nation's newborn screening education center for families and providers. This site provides information and resources about screening at the local, state, and national levels and serves as the Clearinghouse for newborn screening information.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Newborn Screening"},{"id":1321,"resourceId":1982,"resourceName":"National Newborn Screening and Global Resource Center","descriptionText":"<a href='https://www.newbornscreening.info/iva-isovaleric-acidemia/' target='_blank'>National Newborn Screening and Global Resource Center</a> (NNSGRC) provides information and resources in the area of newborn screening and genetics to benefit health professionals, the public health community, consumers and government officials.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Newborn Screening"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='https://rarediseases.org/rare-diseases/tyrosinemia-type-1/' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/949816-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=882' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1535,"resourceId":2166,"resourceName":"ACTion (ACT) sheet","descriptionText":"An  <a href='https://www.acmg.net/PDFLibrary/Tyrosine.pdf' target='_blank'>ACTion (ACT) sheet </a> is available for this condition that describes the short-term actions a health professional should follow when an infant has a positive newborn screening result. ACT sheets were developed by experts in collaboration with the American College of Medical Genetics.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Newborn Screening"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=tyrosinemia' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1538,"resourceId":2169,"resourceName":"MeSH®","descriptionText":"<a href='https://meshb.nlm.nih.gov/record/ui?ui=D020176' target='_blank'>MeSH®</a> (Medical Subject Headings) is a terminology tool used by the National Library of Medicine. Click on the link to view information on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1546,"resourceId":2174,"resourceName":"Algorithm","descriptionText":"An <a href='https://www.acmg.net/PDFLibrary/Tryosine-Elevated-Algorithm.pdf' target='_blank'>Algorithm</a> flowchart is available for this condition for determining the final diagnosis in an infant with a positive newborn screening result. Algorithms are developed by experts in collaboration with the American College of Medical Genetics.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Newborn Screening"},{"id":1547,"resourceId":2175,"resourceName":"Screening, Technology And Research in Genetics (STAR-G) Project","descriptionText":"The <a href='http://www.newbornscreening.info/Parents/aminoaciddisorders/Tyrosinemia.html' target='_blank'>Screening, Technology And Research in Genetics (STAR-G) Project</a> has a fact sheet on this condition, which was written specifically for families that have received a diagnosis as a result of newborn screening. This fact sheet provides general information about the condition and answers questions that are of particular concern to parents.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:276700' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":2999,"questionText":"What is tyrosinemia type 1?","answerText":"<strong>Tyrosinemia type&nbsp;1</strong> is a genetic disorder characterized by elevated blood levels of the amino acid tyrosine, a building block of most proteins. This condition is caused by&nbsp;a shortage of the <a href=\"http://www.genome.gov/glossary/index.cfm?id=58\" target=\"_blank\">enzyme</a> fumarylacetoacetate hydrolase, one&nbsp;of the enzymes required for the multi-step process that breaks down tyrosine.&nbsp;This enzyme shortage is caused by <a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=\"_blank\">mutations</a> in the <a href=\"http://ghr.nlm.nih.gov/gene=fah\" target=\"_blank\"><em>FAH</em></a> <a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">gene</a>. Symptoms usually appear in the first few months of life and include <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000991.htm\" target=\"_blank\">failure to thrive</a>, diarrhea, vomiting, <a href=\"http://www.nlm.nih.gov/medlineplus/jaundice.html\" target=\"_blank\">jaundice</a>, cabbage-like odor, and increased tendency to bleed (particularly nosebleeds). Tyrosinemia type I&nbsp;can lead to liver and kidney failure, softening and weakening of the bones, problems affecting the nervous system, and an increased risk of liver cancer. This condition is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner.[2000] Treatment should be started as soon as the condition is diagnosed and includes a diet restricted in tyrosine and phenylalanine along with nitisinone, a medication that blocks the second step in the tyrosine degradation pathway.[2331][14187]&nbsp; &nbsp;","dateModified":"2017-12-21T00:00:00"},"basicQuestions":[{"questionId":3368,"questionText":"How might tyrosinemia type 1 be treated?","answerText":"There is currently no cure for tyrosinemia type 1. Individuals with this condition need to be on a special diet restricted in two amino acids, tyrosine and phenylalanine, throughout life.&nbsp;Affected individuals may also be treated with a&nbsp;medication called <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00fd1905-27e4-420e-8dc5-a69e4ddc1526\" target=\"_blank\">nitisinone</a>. Treatment should start as soon as the condition is diagnosed.  Some individuals require a liver transplant if their liver disease is already advanced before&nbsp;treatment begins.[2331][14187]<br />\r\n<br />\r\nDetailed information on the treatment of tyrosinemia type 1 is available from <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK1515/#tyrosinemia.Management\" target=\"_blank\">GeneReviews</a>.","dateModified":"2017-12-21T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":2331,"authors":"","articleTitle":"Tyrosinemia: Information for Physicians and Other Health Care Providers","bookWebsiteJournalTitle":"Illinois Department of Public Health Web site","date":"","url":"http://www.idph.state.il.us/HealthWellness/fs/tyrosinemia.htm","dateAccessed":"2010-04-26T00:00:00"},{"referenceId":14187,"authors":"Sniderman King L, Trahms C, Scott CR","articleTitle":"Tyrosinemia Type I","bookWebsiteJournalTitle":"GeneReviews","date":"May 25, 2017","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK1515/","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":26134,"abbreviatedInquiry":"My son is 18 days old and has been diagnosed with tyrosinemia type 1.&nbsp;Is there any hope of curing my son's illness?","caseQuestions":[{"questionId":3368,"questionText":"How might tyrosinemia type 1 be treated?","answerText":"There is currently no cure for tyrosinemia type 1. Individuals with this condition need to be on a special diet restricted in two amino acids, tyrosine and phenylalanine, throughout life.&nbsp;Affected individuals may also be treated with a&nbsp;medication called <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00fd1905-27e4-420e-8dc5-a69e4ddc1526\" target=\"_blank\">nitisinone</a>. Treatment should start as soon as the condition is diagnosed.  Some individuals require a liver transplant if their liver disease is already advanced before&nbsp;treatment begins.[2331][14187]<br />\r\n<br />\r\nDetailed information on the treatment of tyrosinemia type 1 is available from <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK1515/#tyrosinemia.Management\" target=\"_blank\">GeneReviews</a>.","dateModified":"2017-12-21T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":2331,"authors":"","articleTitle":"Tyrosinemia: Information for Physicians and Other Health Care Providers","bookWebsiteJournalTitle":"Illinois Department of Public Health Web site","date":"","url":"http://www.idph.state.il.us/HealthWellness/fs/tyrosinemia.htm","dateAccessed":"2010-04-26T00:00:00"},{"referenceId":14187,"authors":"Sniderman King L, Trahms C, Scott CR","articleTitle":"Tyrosinemia Type I","bookWebsiteJournalTitle":"GeneReviews","date":"May 25, 2017","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK1515/","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":4315,"phenoTypeName":"Generalized aminoaciduria","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10199,"phenoTypeName":"Acute hepatic failure","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5694,"phenoTypeName":"Hepatocellular carcinoma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8115,"phenoTypeName":"Hepatomegaly","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10336,"phenoTypeName":"Rickets of the lower limbs","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":3886,"phenoTypeName":"Splenomegaly","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":15531,"phenoTypeName":"Abnormal bleeding","percentRanges":"-"},{"phenoTypeId":15561,"phenoTypeName":"Abnormality of coagulation","percentRanges":"-"},{"phenoTypeId":3585,"phenoTypeName":"Abnormality of the abdominal wall","percentRanges":"-"},{"phenoTypeId":4096,"phenoTypeName":"Ascites","percentRanges":"-"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":5689,"phenoTypeName":"Cirrhosis","percentRanges":"-"},{"phenoTypeId":2518,"phenoTypeName":"Elevated alpha-fetoprotein","percentRanges":"-"},{"phenoTypeId":4319,"phenoTypeName":"Elevated hepatic transaminase","percentRanges":"-"},{"phenoTypeId":14474,"phenoTypeName":"Elevated urinary delta-aminolevulinic acid","percentRanges":"-"},{"phenoTypeId":6350,"phenoTypeName":"Enlarged kidney","percentRanges":"-"},{"phenoTypeId":1625,"phenoTypeName":"Episodic peripheral neuropathy","percentRanges":"-"},{"phenoTypeId":4081,"phenoTypeName":"Failure to thrive","percentRanges":"-"},{"phenoTypeId":8110,"phenoTypeName":"Gastrointestinal hemorrhage","percentRanges":"-"},{"phenoTypeId":10033,"phenoTypeName":"Glomerulosclerosis","percentRanges":"-"},{"phenoTypeId":10927,"phenoTypeName":"Hypermethioninemia","percentRanges":"-"},{"phenoTypeId":8970,"phenoTypeName":"Hypertrophic cardiomyopathy","percentRanges":"-"},{"phenoTypeId":10923,"phenoTypeName":"Hypertyrosinemia","percentRanges":"-"},{"phenoTypeId":13041,"phenoTypeName":"Hypoglycemia","percentRanges":"-"},{"phenoTypeId":7945,"phenoTypeName":"Hypophosphatemic rickets","percentRanges":"-"},{"phenoTypeId":10052,"phenoTypeName":"Nephrocalcinosis","percentRanges":"-"},{"phenoTypeId":10744,"phenoTypeName":"Pancreatic islet-cell hyperplasia","percentRanges":"-"},{"phenoTypeId":14323,"phenoTypeName":"Paralytic ileus","percentRanges":"-"},{"phenoTypeId":7351,"phenoTypeName":"Periodic paralysis","percentRanges":"-"},{"phenoTypeId":13095,"phenoTypeName":"Renal Fanconi syndrome","percentRanges":"-"},{"phenoTypeId":10015,"phenoTypeName":"Renal insufficiency","percentRanges":"-"}],"medicalProducts":[{"productId":757,"genericName":"Nitisinone","tradeName":"Generic version","tradeLink":"","manufacturer":"","sponsor":"Novitium Pharma","indication":"August 2019, the first generic capsule form of nitisinone was approved for the treatment of hereditary tyrosinemia type 1 (HT) in combination with dietary restriction of tyrosine and phenylalanine.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/nitisinone","medlinePlusLink":""},{"productId":756,"genericName":"Nitisinone","tradeName":"Nityr","tradeLink":"https://www.nityr.us/","manufacturer":"","sponsor":"Cycle Pharmaceuticals Ltd","indication":"July 2017, approved for the treatment of hereditary tyrosinemia type 1 (HT) in combination with dietary restriction of tyrosine and phenylalanine.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/nitisinone","medlinePlusLink":""},{"productId":463,"genericName":"Nitisinone","tradeName":"Orfadin®","tradeLink":"http://www.orfadin.com/","manufacturer":"","sponsor":"Swedish Orphan AB","indication":"Adjunctive therapy to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1. Available in capsule from since Januaray 2009.  Available in oral suspension since April 2016.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Orfadin","medlinePlusLink":""}],"EncodedName":"Tyrosinemia_type_1"}